Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: James Evans, Mitchell Weiss, J. Paul Taylor, Kim Nichols

Premium

Myriad Genetics announced that James Evans will retire as its CFO "in order to attend to family health issues." Evans will continue to perform his duties until a replacement is found. Myriad said it will hire an executive search firm to identify candidates for consideration.

Evans joined Myriad in 1995 as corporate controller and was promoted to VP of finance in July 2005. He became CFO in November 2007. Evans played a leading role in Myriad's recent acquisitions of Rules-Based Medicine and Crescendo Biosciences.


St. Jude Children's Research Hospital has appointed three internationally renowned physician-scientists to leadership positions -- Mitchell Weiss, J. Paul Taylor, and Kim Nichols.

Weiss, professor of pediatrics at the University of Pennsylvania, will chair St. Jude's hematology department.

Taylor, who joined the hospital in 2008, will now chair St. Jude's new department of cell and molecular biology, and hold the Edward F. Barry Endowed chair in cell and molecular biology.

Nichols, director of the CHOP Pediatric Hereditary Cancer Predisposition Program, will launch St. Jude's new division of hereditary cancer predisposition within the oncology department.

Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.